Europe gives green light to AbbVie hepatitis C medicine, others

November 21, 2014 12:21 PM

12 0

LONDON (Reuters) - European regulators recommended approval for AbbVie's hepatitis C drug dasabuvir, an experimental all-oral regimen for patients infected with the virus that could be an alternative to long courses of a combination of pills and injections.

Sanofi's eliglustat, a medicine to treat the rare genetic disorder type 1 Gaucher disease that was approved in the United States in August, was also recommended in Europe.

Read more

To category page